Argenx SE (NASDAQ:ARGX) reported first-quarter earnings on Thursday that exceeded Wall Street forecasts, although revenue came in slightly below analyst expectations as the company continued to post strong growth for its VYVGART franchise.
Shares rose 0.76% in premarket trading following the announcement.
Profit beats forecasts as VYVGART sales continue to expand
The immunology company posted adjusted earnings of $5.52 per share, surpassing the analyst consensus estimate of $5.45 by $0.07.
Quarterly revenue totaled $1.3 billion, narrowly missing analyst expectations of $1.32 billion. However, revenue still increased 63% year-over-year from $790 million recorded in the first quarter of 2025.
Performance was primarily driven by global net product sales of VYVGART.
“Argenx continues to deliver meaningful impact for patients, reflected by our 17th consecutive quarter of VYVGART growth,” said Karen Massey, Chief Executive Officer of argenx. “Looking ahead, VYVGART has the potential to become the first and only approved therapy across MG, pending FDA decisions on label expansions into seronegative and ocular populations.”
FDA decision approaching for expanded indication
Argenx faces an important regulatory catalyst on May 10, 2026, when the U.S. Food and Drug Administration is expected to issue a decision regarding an expanded label for VYVGART.
The proposed expansion would cover patients with anti-acetylcholine receptor antibody negative generalized myasthenia gravis, including MuSK+, LRP4+, and triple seronegative populations.
Net profit more than doubles
The company reported quarterly net profit of $366 million, representing a 116% increase from $169 million in the same period last year.
Research and development expenses rose to $443 million from $311 million a year earlier as Argenx continued advancing its pipeline programs.
Selling, general, and administrative expenses also increased, climbing to $355 million from $276 million in the prior-year quarter.
Pipeline readouts expected later this year
Argenx said it expects topline results from its ALKIVIA study in myositis during the third quarter of 2026.
The company also anticipates results from its EMPASSION study in multifocal motor neuropathy during the fourth quarter.
More about Argenx
Argenx is a biotechnology company focused on developing antibody-based therapies for autoimmune diseases and severe immune disorders. Its lead product, VYVGART, is used in the treatment of generalized myasthenia gravis, while the company continues expanding its pipeline across multiple immunology indications.